AI assistant
Sending…
TransMedics Group, Inc. — Director's Dealing 2020
Feb 5, 2020
31201_dirs_2020-02-05_50f439e5-34e5-4534-beb4-9e3f00fd3401.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: TransMedics Group, Inc. (TMDX)
CIK: 0001756262
Period of Report: 2020-02-03
Reporting Person: Carey John F (VP of Operations)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-02-03 | Common Stock | M | 2000 | $0.39 | Acquired | 3200 | Direct |
| 2020-02-03 | Common Stock | S | 2000 | $17.71 | Disposed | 1200 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-02-03 | Stock Option (Right to Buy) | $0.39 | M | 2000 | Disposed | 2021-09-27 | Common Stock (2000) | Direct |
Footnotes
F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $17.54 to $17.91, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: The option is fully vested.
More from TransMedics Group, Inc.
Regulatory Filings
2026
May 21
Annual Report
2026
Apr 10
Proxy Solicitation & Information Statement
2026
Apr 10
Director's Dealing
2026
Mar 4
Director's Dealing
2026
Mar 4
Regulatory Filings
2026
Feb 27
Annual Report
2026
Feb 24
Regulatory Filings
2026
Feb 24
Director's Dealing
2026
Feb 20
Regulatory Filings
2026
Feb 4